Navigation Links
The risk of developing deep vein thrombosis during a flight is often overestimated
Date:7/23/2009

This release is available in German.

The risk of developing deep vein thrombosis during a long flight is often overestimated. According to the German Institute for Quality and Efficiency in Health Care (IQWiG), this condition is very unlikely in healthy travellers. When people wear a cast or splint after a sports accident, on the other hand, many are not aware that they have an increased risk of deep vein thrombosis in their leg and pelvic area. This is emphasised in information published today on IQWiG's website Informed Health Online.

Blood clots can travel to lungs, leading to pulmonary embolism

If you are unable to move your legs regularly, blood flow through your veins is slower than usual. As a result, blood may clump together, forming a blood clot which can lead to deep vein thrombosis. "This can become dangerous if the blood clot dislodges, travels to the lungs and blocks a blood vessel there," says the Institute's Director, Professor Peter Sawicki. "This complication, called a pulmonary embolism, can reduce the supply of oxygen to the body's cells, overstrain the heart and even cause heart failure."

Even in higher-risk groups the risk of air-travel-related thrombosis is still well below half a percent

During the travel season we often hear that long-haul flights increase the risk of deep vein thrombosis (sometimes called "economy class syndrome"). The Institute summarised the results of research on deep vein thrombosis and air travel, involving the experiences of millions of air travellers. They found that only about 2 to 5 out of every 10,000 people who took a flight longer than 6 to 8 hours developed deep vein thrombosis that caused symptoms (at the most 0.05%). Even people who had a higher risk for example, because they had large varicose veins or were very overweight were not highly likely to develop deep vein thrombosis: only 20 out of every 10,000 travellers were affected (0.2%). The Institute did not find any convincing evidence that people who flew for less than 4 to 6 hours had an increased risk of thrombosis.

"By the way," says Professor Sawicki, "if you want to lower your risk by wearing compression stockings, you should put them on at least 2 hours before the flight and keep them on throughout the entire journey. Research has shown that these stockings lower the risk of deep vein thrombosis somewhat when used in this way."

Wearing a cast or splint increases the risk of deep vein thrombosis

If people have to wear a cast or splint, for example after fracturing a bone or tearing a ligament, they can only move their leg a little bit, if at all. Many people do not know that this also increases the risk of developing a blood clot in a vein in their leg or pelvis. "To prevent serious complications, it is important to get back on your feet and move around again as soon as possible," stresses Professor Sawicki. "If that is not possible, for example because putting strain on the leg too soon could slow down recovery, there are effective medications that can be used." These so-called "anticoagulant" medications reduce the blood's ability to clot. Heparins are among the most established anticoagulant medications. They are injected subcutaneously (under the skin).


'/>"/>

Contact: Hilda Bastian
information@iqwig.de
49-221-356-850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Related medicine news :

1. Clinical Research Safety and Ethical Standards in Developing World Up to U.S. Levels, Report Says
2. Brazil proves developing countries can use generic medicines to fight HIV/AIDS epidemic
3. Researchers identify individuals at risk for developing colon cancer
4. Rare sheep could be key to better diagnostic tests in developing world, says Stanford study
5. Living Alone Increases Odds of Developing Dementia
6. Research output in developing countries reveals 194 percent increase in five years
7. Leeds engineers developing bullet proof vests from cement
8. Prospect Therapeutics Inc.s GCS-100 Has Focused on Developing Treatment for Three Blood-Borne Cancers
9. Caucasians are at higher risk of developing Ewings sarcoma than other races
10. Thomson Reuters Partners with Research4Life to Bring Scientific Research Information Resources to Developing Countries Around the World
11. UCF researcher developing computer program to detect, measure brain tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental ... Your Mouth?” (WIYM) campaign to inform dentists and patients about the safety issues related ... and prosthetic market in the U.S. is projected to reach $6.4 billion in 2018 ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today announced ... was set up in 2006 as a non-profit organization to unite pharmaceutical and ...
(Date:12/8/2016)... ... 08, 2016 , ... Healthcare is in flux. The GOP ... the mass media launching of story movements to highlight what's most unfair about ... experiences; such a movement can generate the network power to improve healthcare policies ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp Insurance, an ... around the greater Phoenix metropolitan region, is announcing a charity event to provide ... the Homeless Youth Connection is to promote community awareness of the ongoing needs ...
(Date:12/7/2016)... ... 07, 2016 , ... DrugDev again demonstrated its dedication to reducing ... the early adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department of Commerce. ... sides of the Atlantic with a mechanism to comply with EU data protection requirements ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016   TriNetX , the health research ... signed a membership agreement to join the ... new cures. The TriNetX network is ... patients globally, biopharmaceutical companies and contract research organizations ... design, site selection, patient recruitment, and collaborative research ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals International, ... VRX) ("Valeant") today announced positive results from a ... to assess the safety and efficacy of IDP-118 ... of plaque psoriasis. Within the ... moderate to severe psoriasis, IDP-118 showed statistical significance ...
(Date:12/8/2016)... 8, 2016  EIP Pharma, LLC ( www.eippharma.com ... for neflamapimod (previously code named VX-745), with the ... trials that demonstrated significant Alzheimer,s disease relevant pharmacological ... and Study 303 (6-week treatment) are the subject ... Disease (CTAD) scientific conference in San ...
Breaking Medicine Technology: